Accès ouvert
2025
article
OpenAlex
Rebecca Sophie Kristeleit, S. Ghamande, Alla Sergeevna Lisyanskaya, A. Oaknin et autres
BACKGROUND: We report the long-term efficacy and safety from the multicenter, randomized, double-blind, placebo-controlled, phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 (NCT03522246) study of first-line rucaparib maintenance for advanced ovarian cancer. PATIENTS AND METHODS: Patients were randomized 4 : 1 to oral rucaparib + intravenous (i.v.) …
gb, us, ru, es, kr, au, it, ca, gr, tw, tr, pl, il, cz, jp
(code pays fourni par la source)
Accès ouvert
2023
supplementary-materials
OpenAlex
Priyanka Sharma, Sara López‐Tarruella, José Á. García-Sáenz, Claire Ward et autres
Supplemental material contains names of participating institutions for the Spanish MMJ-CAR-2014-01 cohort, details on local guidelines for positive family history, tables depicting the relationship between pathological response and family history, pathological response and ER/PR status and univariate analysis of predictors of RCB …
Accès ouvert
2023
supplementary-materials
OpenAlex
Priyanka Sharma, Sara López‐Tarruella, José Á. García-Sáenz, Claire Ward et autres
Supplemental material contains names of participating institutions for the Spanish MMJ-CAR-2014-01 cohort, details on local guidelines for positive family history, tables depicting the relationship between pathological response and family history, pathological response and ER/PR status and univariate analysis of predictors of RCB …
Accès ouvert
2023
other
OpenAlex
Priyanka Sharma, Sara López‐Tarruella, José Á. García-Sáenz, Claire Ward et autres
Abstract Purpose: Recent studies demonstrate that addition of neoadjuvant (NA) carboplatin to anthracycline/taxane chemotherapy improves pathologic complete response (pCR) in triple-negative breast cancer (TNBC). Effectiveness of anthracycline-free platinum combinations in TNBC is not well known. Here, we report efficacy of NA carboplatin …
Accès ouvert
2023
other
OpenAlex
Priyanka Sharma, Sara López‐Tarruella, José Á. García-Sáenz, Claire Ward et autres
Abstract Purpose: Recent studies demonstrate that addition of neoadjuvant (NA) carboplatin to anthracycline/taxane chemotherapy improves pathologic complete response (pCR) in triple-negative breast cancer (TNBC). Effectiveness of anthracycline-free platinum combinations in TNBC is not well known. Here, we report efficacy of NA carboplatin …
Accès ouvert
2020
article
OpenAlex
Antoni C. Picornell, Javier Cortés, Priyanka Sharma, María Isabel Palomero et autres
Recent studies demonstrate that addition of neoadjuvant (NA) carboplatin (Cb) to anthracycline/taxane chemotherapy improves pathological complete response (pCR) in triple negative breast cancer (TNBC). Effectiveness of anthracycline-free, platinum combinations in TNBC is not well known. Here we report efficacy of NA carboplatin …
us
(code pays fourni par la source)
Accès ouvert
2016
article
OpenAlex
Priyanka Sharma, Sara López‐Tarruella, José Á. García-Sáenz, Claire Ward et autres
PURPOSE: Recent studies demonstrate that addition of neoadjuvant (NA) carboplatin to anthracycline/taxane chemotherapy improves pathologic complete response (pCR) in triple-negative breast cancer (TNBC). Effectiveness of anthracycline-free platinum combinations in TNBC is not well known. Here, we report efficacy of NA carboplatin + …
us, es, pe
(code pays fourni par la source)
2015
conference-abstract
OpenAlex
Priyanka Sharma, Bruce F. Kimler, Jennifer R. Klemp, Claire Ward et autres
1092 Background: Randomized studies have demonstrated that Neoadjuvant Chemotherapy (NAC) is equivalent to adjuvant chemotherapy (AdjC) in operable breast cancer (BC). However, the differential impact of NAC vs AdjC on outcomes in various BS subtypes is not known. Specifically, the impact of …
us
(code pays fourni par la source)
2015
conference-abstract
OpenAlex
Priyanka Sharma, Bruce F. Kimler, Jennifer R. Klemp, Claire Ward et autres
e12071 Background: Adjuvant chemotherapy is recommended for most patients with stage I-III triple negative breast cancer (TNBC). Anthracycline (A) and Taxane (T) form the backbone of most adjuvant regimens. One randomized study has demonstrated that 4 cycles of Docetaxel/Cyclophosphamide (TC) is superior …
us
(code pays fourni par la source)
2015
conference-abstract
OpenAlex
Qamar J. Khan, Anne P. O’Dea, Carol J. Fabian, Carol Sue Connor et autres
1039 Background: Adjuvant trials have demonstrated that addition of trastuzumab (T) to chemotherapy reduces risk of recurrence and death in women with HER2 overexpressed or gene amplified early breast cancer (BC). Central testing of specimens from patients in NSABP B-31 demonstrated that …
us
(code pays fourni par la source)
2015
conference-abstract
OpenAlex
Priyanka Sharma, Benjamin Powers, Bruce F. Kimler, Claire Ward et autres
Abstract Introduction: Growing evidence demonstrates activity of neoadjuvant carboplatin in triple negative breast cancer (TNBC). Underlying germline and somatic Homologous Recombination (HR) repair deficiency may predict response to DNA damaging agents like platinum compounds in TNBC. Certain DNA repair machinery genes (Fanconi …
us
(code pays fourni par la source)
2014
article
OpenAlex
Carol Sue Connor, Bruce F. Kimler, Joshua M.V. Mammen, Marilee McGinness et autres
BACKGROUND: We evaluated the impact of Neoadjuvant Chemotherapy (NAC) versus primary surgery (PS) on axillary disease burden/surgery in clinically node negative Triple Negative Breast Cancer (TNBC). METHODS: Two hundred forty-three Stage I-III TNBC patients have enrolled on an IRB approved multisite prospective …
us
(code pays fourni par la source)